

November 22, 2025

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex,
Bandra (East),
Mumbai - 400 051

Scrip code: 512529

Scrip code: SEQUENT

Dear Sir/ Madam,

Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2025 ("SEBI Listing Regulations").

Ref: Composite Scheme of amalgamation amongst Sequent Scientific Limited ("Sequent"), Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, S.V. Labs Private Limited, Vindhya Organics Private Limited, Viyash Life Sciences Private Limited ("Viyash"), Geninn Life Sciences Private Limited ("Geninn") and Sequent Research Limited and their respective shareholders and the creditors ("Scheme").

With reference to our letter dated November 20, 2025, informing about the receipt of the certified copy of the NCLT order sanctioning the Scheme, we have been informed that Viyash has fixed Saturday, November 1, 2025, as the **Record Date 1** (*as defined in the Scheme*) for determining names of the equity shareholders of Geninn who shall be entitled for allotment of equity shares by Viyash, as Merger Consideration Shares 1 (*as defined in the Scheme*). The Share Exchange Ratio 1 (*as defined in the Scheme*) is as below:

Share exchange ratio 1: 47 (Forty-Seven) equity shares of Viyash of Rs. 10/- each fully paid for every 1 (One) equity share of Geninn of Rs. 10/- each fully paid up.

Kindly take the same on record.

Thanking you,

Yours faithfully,
For **Sequent Scientific Limited**

Yoshita Vora
Company Secretary & Compliance Officer

SeQuent Scientific Limited

Registered Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

Tel No.: +91 9391139986 / 22-4111 4777 | **CIN:** L99999TS1985PLC196357

Website: <http://www.sequent.in> | **Email Id:** investorrelations@sequent.in